| Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab+ Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study JW Smithy, HL Kalvin, FD Ehrich, R Shah, M Adamow, V Raber, ... Clinical Cancer Research, OF1-OF9, 2024 | | 2024 |
| A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. A Betof Warner, JW Smithy, MA Postow, K Panageas, AJ Schoenfeld, ... Journal of Clinical Oncology 42 (16_suppl), TPS9603-TPS9603, 2024 | | 2024 |
| Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment … MN Becker, KM Rosenthal, A Betof Warner, A Daud, EJ Lipson, ... Journal of Clinical Oncology 42 (16_suppl), e13548-e13548, 2024 | | 2024 |
| A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors. AJ Schoenfeld, A Betof Warner, JA Chesney, SS Thomas, O Hamid, GK In, ... Journal of Clinical Oncology 42 (16_suppl), TPS9599-TPS9599, 2024 | | 2024 |
| Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies J Haanen, C Los, GQ Phan, A Betof Warner American Society of Clinical Oncology Educational Book 44 (3), e431608, 2024 | | 2024 |
| Abstract CT285: Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients … SS Thomas, JA Chesney, O Hamid, GK In, AN Shoushtari, Y Samhouri, ... Cancer Research 84 (7_Supplement), CT285-CT285, 2024 | | 2024 |
| Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy ST Chen, YR Semenov, A Alloo, DQ Bach, AB Warner, A Bougrine, ... Journal for Immunotherapy of Cancer 12 (4), 2024 | | 2024 |
| Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy AB Warner, O Hamid, K Komanduri, R Amaria, MO Butler, J Haanen, ... Journal for immunotherapy of cancer 12 (2), 2024 | 5 | 2024 |
| The features and management of acquired resistance to PD1-based therapy in metastatic melanoma A Hepner, JM Versluis, R Wallace, C Allayous, LJ Brown, C Trojaniello, ... European Journal of Cancer 196, 113441, 2024 | 1 | 2024 |
| Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers R Malani, A Bhatia, AB Warner, JT Yang Seminars in Neurology, 2023 | 1 | 2023 |
| 789 Immune checkpoint blockade augments cyclophosphamide induced anti-tumor immunity by expanding effector CD8+ T cell clones in a preclinical melanoma model MM George, L Hamadene, NJ Ceglia, Y Marouf, D Hirschhorn, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants D Hirschhorn, S Budhu, L Kraehenbuehl, M Gigoux, D Schröder, A Chow, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma A Kirane, MC Lowe, MU Ahmad, S Sharma, M Serasanambati, AB Warner, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| CD4+ TIL to the Rescue of Anti–PD-1 Failure by Targeting MHC-II A Betof Warner, JJ Luke Clinical Cancer Research 29 (19), 3829-3831, 2023 | | 2023 |
| Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions A Betof Warner Cancer Immunology Research 11 (9), 1158-1158, 2023 | | 2023 |
| Real‐world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy S Lee, AV Bennett, X Zhou, A Betof Warner, JG Trogdon, EE Kent, ... Pharmacoepidemiology and Drug Safety 32 (9), 988-1000, 2023 | 1 | 2023 |
| Diversity, equity, and inclusion in the melanoma research community ME Portuallo, DY Lu, GM Alicea, J Bolling, R Lee, J McQuade, AB Warner, ... Pigment cell & melanoma research 36 (5), 441-447, 2023 | 1 | 2023 |
| Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy) PA Ascierto, SS Agarwala, AB Warner, MS Ernstoff, BA Fox, TF Gajewski, ... Journal of Translational Medicine 21 (1), 508, 2023 | 2 | 2023 |
| Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study RC Augustin, Z Huang, F Ding, S Zhai, J McArdle, A Santisi, M Davis, ... Frontiers in Oncology 13, 1075823, 2023 | 7 | 2023 |
| A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases. A Betof Warner, MA Postow, K Panageas, JW Smithy, AJ Schoenfeld, ... Journal of Clinical Oncology 41 (16_suppl), TPS9606-TPS9606, 2023 | 1 | 2023 |
Alexander N. ShoushtariAssistant Attending Physician, Memorial Sloan Kettering Cancer CenterVerified email at mskcc.org